<DOC>
	<DOCNO>NCT00645476</DOCNO>
	<brief_summary>Memantine glutamate NMDA receptor antagonist show efficacy cognitive dysfunction due moderate severe Alzheimer disease ( Reisberg et al. , 2003 ) . The investigator propose treat 75 subject bipolar disorder minimal mood symptom cognitive dysfunction memantine placebo . The 75 subject enrol three site . The study perform three site , site function independently . The investigator study include objective neuropsychological test memory executive function treatment , well rating mood symptom subjective patient rating memory function every study visit . The principal aim study measure efficacy memantine improve memory function minimally symptomatic subject bipolar disorder . The investigator hypothesize minimally symptomatic subject bipolar disorder memantine efficacious improve cognitive function , measure difference neuropsychological test score begin end trial . Secondary analysis test role memantine improve residual mood symptom ( depression mania ) subject bipolar disorder . Demonstrating role memantine reduce cognitive dysfunction minimally symptomatic subject bipolar disorder promise provide important clinical information , could lead improvement well-being functional status large population subject bipolar disorder . There optional open label 12-week extension study . Subjects restart memantine similar regimen first phase study . Subjects meet investigator every four week ( week 16 , 20 , 24 ) assessment mention . Neuropsychological testing repeat week 24 . It investigator 's belief add timeline well demonstrate improvement cognitive function .</brief_summary>
	<brief_title>Memantine Cognitive Dysfunction Bipolar Disorder</brief_title>
	<detailed_description>Study : MEMANTINE AND COGNITIVE DYSFUNCTION IN BIPOLAR DISORDER The study design involve double-blind , prospective , longitudinal treatment flexible dos memantine placebo 12 week minimally symptomatic subject bipolar disorder memory dysfunction . We use objective neuropsychological test memory function treatment , well subjective patient rating memory throughout treatment . The primary analysis compare neuropsychological test score treatment among subject treat memantine placebo . A minimum 25 subject bipolar disorder enrol . We enroll subject bipolar disorder , diagnose use Structured Clinical Interview DSM-IV-TR Mood Module ( SCID Mood Module ) ( screen visit ) . Subjects baseline score 17-item Hamilton Depression Rating Scale Young Mania Rating Scale 10 low . Both instrument administer trained raters . Visit Timeline : Screen : Week -2 ; Baseline Visit : Week 0 ; Visit 1Week 4 ; Visit 2Week 8 ; Visit 3Week 12</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Inclusion criterion : follow condition must meet patient eligibility : DSMIV diagnostic criterion bipolar disorder ( type I , type II , NOS ) ( diagnose use Structured Clinical Interview DSMIVTR Mood Module ( SCID Mood Module ) Written informed consent Men woman age 1865 A baseline HamiltonD 17 score &lt; 10 screen baseline visit . A baseline YMRS score &lt; 10 screen baseline visit . No acute episode depression mania previous 12 week . MGH Cognitive Physical Functioning Scale : Cutoff : &gt; 15 Everyday Cognition SelfReport Form : Average item &gt; 1.5 orRBANS : &lt; 12 year education , RBANS total scale score &lt; 85 =12 year education , RBANS total scale score &lt; 93 &gt; 12 year education , RBANS total scale score &lt; 100 Able read understand English . Patients meet follow criterion exclude study : Subjects suicidal ideation outpatient treatment determine unsafe study clinician . These patient immediately refer appropriate clinical treatment . Pregnant woman , nurse mother , woman childbearing potential use medically accept mean contraception ( defined oral contraceptive pill implant , condom , diaphragm , spermicide , IUD , s/p tubal ligation , partner vasectomy ) . Serious unstable medical illness , include liver impairment , kidney impairment , cardiovascular , hepatic , respiratory , endocrine , neurologic hematologic disease . History seizure disorder , brain injury , history know neurological disease ( multiple sclerosis , degenerative disease ALS , Parkinson disease movement disorder , etc ) . History current diagnosis follow DSMIV psychiatric illness : organic mental disorder , schizophrenia , schizoaffective disorder , delusional disorder , psychotic disorder otherwise specify , major depressive disorder , patient substance dependence disorder , include alcohol , active within last 12 month . History multiple adverse drug reaction . Patients mood congruent mood incongruent psychotic feature within last 12 month . Clinical laboratory evidence hypothyroidism . Patients episode acute depression mania 12 week prior enrollment . Patients electroconvulsive therapy ( ECT ) within 6 month precede enrollment . Patients take drug alkalinize urine ( e.g. , carbonic anhydrase inhibitor , sodium bicarbonate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>DSM-IV diagnostic criterion bipolar disorder ( type I , type II , NOS )</keyword>
	<keyword>( diagnose use Structured Clinical Interview DSM-IV-TR Mood Module ( SCID Mood Module )</keyword>
</DOC>